Gilead Reaches New 52-Week High (GILD)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Friday as it is currently trading at $54.07, above its previous 52-week high of $49.63 with 25.8 million shares traded as of 1:10 p.m. ET. Average volume has been 9.5 million shares over the past 30 days.
Gilead has a market cap of $35.81 billion and is part of the
sector and
industry. Shares are up 20.5% year to date as of the close of trading on Thursday.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. The company has a P/E ratio of 14.3, above the average drugs industry P/E ratio of 13.8 and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Gilead as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
